Comprehensive review discusses the immunological basis for exceptional responsiveness to PD-1 and CTLA-4 inhibitors in dMMR-MSI-H colorectal cancer, along with emerging resistance mechanisms and predictive biomarkers. (Front Immunol)
Review examines immune checkpoint inhibitors in dMMR-MSI-H CRC
The CRC Digest